eli lilly

A man in Gurgaon was allegedly producing fake Mounjaro injections and selling his own unapproved brand, 'Toneup', disguised as a Japanese product. Authorities recalled 22 Toneup injections after tracing sales to multiple cities. The accused learned to make injections using online resources and sourced materials from China.

Lower-cost, latest-generation immunotherapies from China are a shot in the arm for Indian cancer patients who have been priced out of treatment by expensive drugs from western MNCs

Raw Material Source Tracked, Flat In Gurgaon Used to Assemble Injections

Authorities have uncovered a dual operation in Gurgaon where a man manufactured fake Mounjaro injections and an unapproved tirzepatide-based product named 'Toneup'. Using 3D printing for packaging, he sold these counterfeit and unapproved vials online, with some traced to buyers in Delhi and Hyderabad. The investigation is ongoing, and an immediate recall has been initiated.

Affordable generic versions of Ozempic and Wegovy have quickly secured 20% of the Rs 1,600 crore weight-loss market following patent expiry. Early movers like Torrent and Sun Pharma are challenging eli lilly's Mounjaro, with generics and lower pricing boosting semaglutide's market position.

The UAE has approved Foundayo (orforglipron), eli lilly's once-daily oral obesity pill, becoming one of the first countries globally to offer a needle-free alternative. This GLP-1 receptor agonist mimics natural hormones to regulate appetite and blood sugar, aiding weight loss and improving metabolic health. Available by prescription from May 2026, it's intended for long-term use alongside lifestyle changes.

It is not a quick fix. It is not your ‘next-generation weight-loss drug’. It is not a cosmetic solution or something to include in a pre-wedding routine, experts warn. Despite that, the popularity of Mounjaro continues to quietly reshape the narrative around fitness, beauty and confidence

NEW DELHI: US-based pharmaceutical company eli lilly and company is close to inking a deal with two companies to globally source gastrointestinal and tuberculosis bulk drugs from India, a top company official said on Friday.

Sun Pharma on Thursday claimed victory over eli lilly and Co in a patent litigation over Gemzar, used in cancer treatment, with a US federal court ruling in its favour.

NEW DELHI: eli lilly is planning to make India a major sourcing base for global supply of drugs. The pharmaceutical MNC has also identified a suit of patented cancer and diabetes drugs, currently under development in the US, to launch in the Indian market post 2005.

MUMBAI: Ranbaxy Laboratories' management has decided to divest its stake from eli lilly Ranbaxy Ltd. The company has also decided to to take stake in Gufic Pharma from its promoters. The company, it is learnt has already acquired 17 brands from the company.

MUMBAI: Ranbaxy Laboratories' management has decided to divest its stake from eli lilly Ranbaxy Ltd. The company has also decided to to take stake in Gufic Pharma from its promoters. The company, it is learnt has already acquired 17 brands from the company.

BANGALORE: eli lilly India on Wednesday launched a new drug for juvenile diabetics, even as it declared that it would not start an insulin price war, with Wockhardt dropping the rates earlier this week.

Indian pharmaceutical giants like Sun Pharma, Torrent, and Dr. Reddy's have launched affordable semaglutide, a groundbreaking weight-loss drug, following Novo Nordisk's patent expiry. This move significantly reduces therapy costs, offering patients greater access to treatment for obesity and type-2 diabetes. Torrent Pharma even introduced both oral and injectable versions, marking a significant step in addressing India's growing metabolic disorder crisis.

eli lilly India announced its entry in the branded generics segment with the launch of Lil Therapeutics, an expansion of its oncology division that will help expand delivery of cancer drugs to patients at an affordable cost.

American pharmaceutical giant eli lilly and Company is investing over $1 billion (approx Rs 8,900 crore) in India to establish new contract manufacturing facilities, including a significant hub in Hyderabad. This strategic move aims to bolster its global manufacturing and supply capabilities, leveraging India's skilled workforce to develop and produce medicines for critical ailments.

Dr Reddy's Laboratories on Tuesday said it has inked a licensing pact with eli lilly and Company to produce Baricitinib in the country for treatment of Covid-19.